Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia: early-phase trial registry
159 of 307 indexed Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #26 of 28,707 conditions by registered trial count.
307 US clinical trials · 159 currently recruiting · #26 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia: 307 US clinical trials tracked, 159 recruiting.
Acute Myeloid Leukemia is the subject of 307 registered US clinical trials on ClinicalTrials.gov, 159 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 265 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 38 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia
OPEN 159 | RECR 52% | LATE 13 | EARLY 265 | RANK #26 | SPON 38
Volume-matched condition peers
Nearest open-share peer: Aortic Stenosis (52% recruiting · 27 trials)
Acute Myeloid Leukemia lists 159 open slots (52% of 307 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia is recruiting above its size-band peers.
159 of 307 indexed trials (51.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Myeloid Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 38 of 307 trials (12.4%). 128 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 307 trials that report a genuine target (sentinel values excluded). 223 of those (72.6%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia research is mostly interventional.
290 interventional and 17 observational studies make up this index (94.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
307 total, page 2 of 7
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT04774393
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Stemline Therapeutics
NCT06456463
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04047641
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Edgewood Oncology
NCT04243785
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Mayo Clinic
NCT06279572
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT03128034
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
NCT03422731
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03661307
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
NCT03113643
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT05735717
Massage Impact on Sleep in Pediatric Oncology
Children's Hospital of Philadelphia
NCT06892158
Cardioprotection in AML
University of Virginia
NCT04977180
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Washington University School of Medicine
NCT06158828
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT05031897
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03383575
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
NCT04797767
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Pilot Imaging Study of Leukemia
University of Oklahoma
NCT03633955
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
University of Alabama at Birmingham
NCT06323590
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
NCT06399640
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
NCT03630991
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
NCT03969446
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06013423
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT06484062
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Joshua Zeidner
NCT05442216
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT04128748
A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT07356154
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx
NCT04872478
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT04024761
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
University of Washington
NCT06710418
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics
NCT06146257
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
National Cancer Institute (NCI)
NCT06514261
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Masonic Cancer Center, University of Minnesota
NCT06594445
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Sawa Ito, MD
NCT06529731
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT07392242
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Karen Ballen, MD
NCT05233618
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT06769490
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT06498973
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
M.D. Anderson Cancer Center
NCT05360160
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT05010122
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
OHSU Knight Cancer Institute
NCT06504459
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
NCT05322850
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
NCT06191978
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT05748197
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT06128070
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT05986240
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
H. Lee Moffitt Cancer Center and Research Institute
NCT06511882
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05796570
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT06928662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 160 |
| Phase 2 | 105 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia page
307 registered trials, 159 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 159 Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia condition card totals 307 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.